Screener
Immunovant, Inc. IMVT Return on equity
Return on equity at other companies
Other financials
Where this comes from
Calculated from Immunovant, Inc.’s reported figures.
Based on trailing twelve months.
The source filing: Immunovant, Inc.’s 10-K, filed May 20, 2026. Open the filing →
- Filed
- May 20, 2026, 7:28 AM EDT
- Fiscal year
- FY2026
- Accession
- 0001764013-26-000064
FAQ
- What is Immunovant, Inc.'s return on equity?
- Immunovant, Inc. (IMVT) reported return on equity of -64.8% in Q1 2026.
- How has Immunovant, Inc.'s return on equity changed year-over-year?
- Immunovant, Inc.'s return on equity decreased by 3.8% year-over-year, from -62.5% to -64.8%.
- What is the long-term trend for Immunovant, Inc.'s return on equity?
- Over 5 years (2021 to 2026), Immunovant, Inc.'s return on equity has grown at a 7.9% compound annual growth rate (CAGR), from -44.3% to -64.8%.
- What does return on equity mean?
- Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.
Ask your AI about Immunovant, Inc.'s return on equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude